NIRMIN 5S

Indications

• Gastroesophageal reflux disease (GERD)
• Peptic ulcers
• Dyspepsia
• Acid-base balance disorders

Dosage

Children: Refer to specific acid formulations and guidelines for dosing. General dosing depends on the acid and its clinical use.

Adults: Refer to specific acid formulations and guidelines for dosing. General dosing depends on the acid and its clinical use.

Mechanism of action

Acids exert their effects primarily by dissociating into protons and anions in solution, thereby lowering the pH of the surrounding environment. This proton donation can influence various physiological processes, including enzyme activity, ion transport, and cellular signaling pathways. For example, hydrochloric acid in the stomach aids in digestion and the absorption of certain nutrients.

Pharmacodynamics

The pharmacodynamic effects of acids are largely dependent on their concentration and the specific type of acid involved. Weak acids may dissociate partially, leading to a less pronounced effect, while strong acids fully dissociate, leading to significant changes in pH and potential tissue irritation. Acids can also interact with various receptors and enzymes, influencing metabolic pathways and physiological responses.

Pharmacokinetics

The pharmacokinetics of acids vary widely depending on their chemical structure. Strong acids, such as hydrochloric acid, do not significantly enter systemic circulation due to their rapid dissociation in aqueous environments. Weak acids may be absorbed through the gastrointestinal tract, where their absorption is influenced by pH, solubility, and the presence of food. Metabolism and excretion pathways also vary, with some acids being metabolized to bicarbonate or other metabolites before excretion, primarily via the kidneys.

Adverse effects

• Gastrointestinal irritation
• Nausea
• Vomiting
• Abdominal pain
• Diarrhea
• Electrolyte imbalance

Precautions

• Use with caution in patients with renal impairment
• Monitor for signs of gastrointestinal bleeding
• Consider potential interactions with other medications that may affect gastrointestinal motility or pH levels

Pregnancy

The safety of various acids during pregnancy may vary; consult specific guidelines for each acid. Generally, use should be limited to essential cases.

Breast-feeding

Caution is advised when using acids during breastfeeding; consult specific guidelines for each acid.

Storage

Store in a cool, dry place away from direct sunlight. Keep tightly closed and out of reach of children.

Indications

• Asthma
• Chronic obstructive pulmonary disease (COPD)
• Bronchospasm associated with respiratory conditions

Dosage

Children: Refer to the BNF for Children for specific paediatric dosing guidelines.

Adults: Refer to the BNF for specific adult dosing guidelines.

Mechanism of action

Aminophylline works as a phosphodiesterase inhibitor, leading to an increase in intracellular cyclic AMP (cAMP). This action results in the relaxation of bronchial smooth muscle, bronchodilation, and reduced airway resistance. It may also exert anti-inflammatory effects by inhibiting the release of inflammatory mediators from mast cells.

Pharmacodynamics

The pharmacodynamics of aminophylline involve its ability to enhance respiratory function by decreasing airway resistance, improving mucociliary clearance, and increasing respiratory muscle strength. Its therapeutic effects typically begin within 30 minutes of administration, with a peak effect occurring within 2 hours.

Pharmacokinetics

Aminophylline is rapidly absorbed following intravenous administration, with a bioavailability of approximately 100%. Its volume of distribution is large, indicating extensive tissue binding. The drug is metabolized primarily in the liver via cytochrome P450 enzymes, with a half-life ranging from 3 to 10 hours depending on patient factors, including age, liver function, and concurrent medications.

Interactions

• aminoglycosides+agalsidasealfa: Severe (decreases effects)
• aminoglycosides+agalsidasebeta: Severe (decreases effects)
• betablockers,selective+aminophylline: Severe (increases risk of bronchospasm)
• aminophylline+phosphodiesterasetype-: Severe (increases exposure)
• stiripentol+aminophylline: Severe (increases exposure)
• deferasirox+aminophylline: Severe (increases exposure)
• aminophylline+roflumilast: Severe (increases exposure)
• aciclovir+aminophylline: Moderate (increases exposure)
• aminophylline+macrolides: Moderate (decreases exposure)
• aminophylline+erythromycin: Moderate (decreases exposure)

Indications

• Constipation
• Diagnostic aid in colonoscopy preparation
• Management of hyperosmolality in various conditions

Dosage

Children: For children, the dosage should be determined based on age and condition, and it is advised to refer to the BNF for Children for specific dosing guidelines.

Adults: The typical dose for adults is 30 to 150 mL of sorbitol solution (70%) taken orally, as needed, usually before bedtime.

Mechanism of action

Sorbitol exerts its laxative effect by drawing water into the large intestine, thereby stimulating bowel movements. It acts as a hygroscopic agent, pulling water from tissues into the feces, which reflexively stimulates evacuation. In metabolic pathways, sorbitol is produced from glucose via aldose reductase and is converted to fructose by sorbitol dehydrogenase, with implications in diabetic complications such as retinopathy.

Pharmacodynamics

Sorbitol's laxative effect results from its osmotic properties, which increase the water content of the stool and soften it, facilitating easier passage. Additionally, sorbitol can induce apoptosis in certain cancer cell lines, indicating potential therapeutic implications beyond its laxative use. The modulation of intracellular signaling pathways through the regulation of proteins such as Bax and Bcl-2 suggests a complex role in cellular health and disease.

Pharmacokinetics

Sorbitol is poorly absorbed in the gastrointestinal tract, which contributes to its efficacy as a laxative. It is metabolized in the liver, primarily through the polyol pathway. The absorption and distribution of sorbitol are affected by its osmotic properties, leading to increased intestinal water retention. Its elimination is primarily via renal excretion, with minimal systemic absorption, thus reducing the risk of systemic side effects.

Adverse effects

• Diarrhea
• Abdominal cramps
• Nausea
• Vomiting
• Electrolyte imbalances

Precautions

• Use with caution in patients with renal impairment
• May exacerbate gastrointestinal conditions

Pregnancy

Sorbitol is generally considered safe during pregnancy, but should be used under medical supervision.

Breast-feeding

Sorbitol is excreted in breast milk in small amounts; consult a healthcare provider before use.

Storage

Store in a cool, dry place, away from direct sunlight.

Formulations

• Oral solution
• Syrup

Mechanism of action

Sorbitol exerts its laxative effect by drawing water into the large intestine, thereby stimulating bowel movements. ... Sorbitol exerts hygroscopic and/or local irritant action, drawing water from tissues into feces and reflexly stimulating evacuation. The polyol pathway consists of two enzymes aldose reductase (AR) and sorbitol dehydrogenase (SDH); the former is the first enzyme in the polyol pathway, that catalyzes the reduction of glucose to sorbitol, the latter is the second one, that converts sorbitol to fructose using by NAD(+) as a cofactor. ... SDH activity, the second step in the polyol pathway, might make a greater contribution to the etiology of diabetic retinopathy than does the first step involving AR. /This paper proposes/ a novel hypothesis that polymorphisms of SDH gene may be correlated with SDH gene expression levels in diabetic retinas, thus being a valuable genetic marker for diabetic retinopathy. It has been reported that sorbitol induces apoptosis in several cancer cell lines. ... In /this/ study, the intracellular signaling pathways of sorbitol-induced apoptosis in human K562 cells were investigated using both morphological analysis and DNA fragmentation technique. In this study, we demonstrated that sorbitol-induced apoptosis in human K562 cells is a concentration- and time-dependent manner. This sorbitol-induced apoptosis in human K562 cells was also accompanied by the up-regulation of Bax, and down-regulation of p-Bcl-2, but no effect on the levels of Bcl-X(L). Moreover, the sorbitol treatment resulted in a significant reduction of mitochondria membrane potential, increase in the release of mitochondrial cytochrome c (cyt c), and activation of caspase 3. Furthermore, treatment with caspase 3 inhibitor (z-DEVD-fmk) was capable of preventing the sorbitol-induced caspase 3 activity and cell death. These results clearly demonstrate that the induction of apoptosis by sorbitol involves multiple cellular/molecular pathways and strongly suggest that pro- and anti-apoptotic Bcl-2 family proteins, mitochondrial membrane potential, mitochondrial cyt c, and caspase 3, they all participate in sorbitol-induced apoptotic process in human K562 cells. Chronic diabetic complications, in particular, nephropathy, peripheral and autonomic neuropathy, "diabetic foot," retinopathy, and cardiovascular disease, remain the major cause of morbidity and mortality in patients with diabetes mellitus. Growing evidence indicates that both increased activity of the sorbitol pathway of glucose metabolism and enhanced oxidative stress are the leading factors in the pathogenesis of diabetic complications. The relation between the two mechanisms remains the area of controversy. One group has reported that increased sorbitol pathway activity has a protective rather than detrimental role in complication-prone tissues because the pathway detoxifies toxic lipid peroxidation products. Others put forward a so-called "unifying hypothesis" suggesting that activation of several major pathways implicated in diabetic complications (eg, sorbitol pathway) occurs due to increased production of superoxide anion radicals in mitochondria and resulting poly(ADP-ribose) polymerase activation. This review (a) presents findings supporting a key role for the sorbitol pathway in oxidative stress and oxidative stress-initiated downstream mechanisms of diabetic complications, and (b) summarizes experimental evidence against a detoxifying role of the sorbitol pathway, as well as the "unifying concept."